The Lilly Merida Biosciences acquisition brings together one of the world’s largest pharmaceutical companies and a clinical-stage biotechnology firm built around a single scientific idea: eliminating the specific antibodies that cause autoimmune and allergic disease, rather than suppressing the immune system as a whole. Eli Lilly and Company (NYSE: LLY) and Merida Biosciences, Inc., headquartered in Cambridge, Massachusetts, announced on August 31, 2026, that they have signed a definitive agreement under which Lilly will acquire Merida. The deal was disclosed jointly from Indianapolis, Lilly’s home base, and Cambridge, Merida’s base, underscoring that this is a combination of an established global drug maker and an emerging precision-immunology innovator.
Under the terms of the agreement, Lilly will pay up to $2.875 billion in cash, a figure that is inclusive of an upfront payment plus contingent milestone payments tied to future development or commercial progress. The exact split between the upfront amount and the milestone payments was not disclosed in the companies’ announcement and is therefore flagged here as undisclosed. The transaction remains subject to customary closing conditions, including regulatory approvals, and the companies expect it to close in the fourth quarter of 2026. Lilly has said it will determine the acquisition’s accounting treatment under Generally Accepted Accounting Principles once the deal closes, after which the transaction will be reflected in the company’s financial results and forward guidance.
At the center of the Lilly Merida Biosciences acquisition is Merida’s antibody-engineering platform, which is designed to selectively degrade pathogenic autoantibodies, the disease-causing agents behind a range of immune-mediated conditions. Rather than dampening the immune system broadly, the way many current immunology drugs do, Merida’s biologics are engineered to target and remove only the antibodies responsible for driving a specific disease, with the stated goal of preserving normal immune function. That precision-targeting approach is the central scientific thesis Lilly is buying into, and it is also the reason company leaders describe the platform as having applications that extend well beyond its current lead program.
Merida’s furthest-along candidate, MER511, is in Phase 1 development for two related thyroid conditions: Graves’ disease and thyroid eye disease, known as TED. Both conditions are driven by thyroid-stimulating immunoglobulins, autoantibodies that activate the thyroid-stimulating hormone receptor. According to the companies, initial Phase 1 data show that MER511 achieved robust reductions in these pathogenic thyroid-stimulating antibodies, alongside a favorable initial safety profile.
Lilly Merida Biosciences Acquisition: Graves’ Disease and Thyroid Eye Disease Unmet Need
Graves’ disease affects approximately 3 million people in the United States, and patients with the condition face elevated cardiovascular risk and mortality. Roughly 25 to 40 percent of people with Graves’ disease go on to develop thyroid eye disease, which can cause pain, disfigurement, and in severe cases, vision loss. Approved treatments already exist for both conditions, but none of them directly target the autoantibodies that cause the disease in the first place, they manage symptoms or downstream effects rather than the underlying antibody-driven mechanism. That gap is precisely what Merida’s platform is designed to close, and it is a central rationale Lilly has offered for pursuing the acquisition.
Francisco Ramírez-Valle, M.D., Ph.D., senior vice president of Lilly immunology research and early clinical development, framed the deal around Lilly’s broader pipeline strategy of pursuing therapies that change the course of disease rather than only its downstream effects. He said Merida’s lead program is designed to “selectively and directly” eliminate the antibodies causing Graves’ disease and thyroid eye disease. Adam Townsend, chief executive officer of Merida, credited the company’s scientific direction to co-founder and chief scientific officer Dario Gutierrez, noting that the team advanced the underlying science from concept to clinical data before agreeing to join Lilly.
Beyond MER511, and central to why the Lilly Merida Biosciences acquisition extends past a single asset, Merida’s pipeline includes MER769, a preclinical-stage program targeting food allergy, asthma, chronic spontaneous urticaria, and other diseases driven by the antibody responsible for triggering allergic reactions. Merida also has earlier-stage programs aimed at kidney diseases such as membranous nephropathy and other immune-mediated conditions, giving Lilly a broader set of assets built on the same antibody-degradation technology rather than a single-asset bet.
Lilly Merida Biosciences Acquisition: Deal Structure, Advisors, and Next Steps
Because pathogenic autoantibodies are understood to drive a wide range of serious diseases, Lilly and Merida both describe the platform’s addressable opportunity, and, by extension, the long-term value of the Lilly Merida Biosciences acquisition, as extending well past thyroid conditions, though no additional specific disease targets beyond those already in Merida’s pipeline were disclosed in the announcement. On the legal and financial side, Ropes & Gray LLP is acting as legal counsel to Lilly, while Centerview Partners LLC is serving as exclusive financial advisor and Goodwin Procter LLP as legal counsel to Merida.
For Lilly, the Lilly Merida Biosciences acquisition adds a differentiated immunology mechanism to a research organization already working across diabetes, obesity, Alzheimer’s disease, oncology, and immune-mediated conditions. For Merida, being absorbed into a larger, well-capitalized organization is framed by its own CEO as a way to give the antibody-degradation science the resources needed to reach patients. Investors and analysts tracking the Lilly Merida Biosciences acquisition will likely watch two things over the coming months: progress toward the expected fourth-quarter 2026 close, including any regulatory review findings, and additional Phase 1 data updates on MER511 in Graves’ disease and thyroid eye disease.
Like most disclosures of this kind, the companies’ announcement of the Lilly Merida Biosciences acquisition includes forward-looking statements, as defined under the Private Securities Litigation Reform Act of 1995, regarding the anticipated benefits of the acquisition and the prospects for Merida’s product candidates. Lilly has cautioned that there is no guarantee the transaction will close, that it will achieve the results discussed in the release, or that it will yield commercially successful products, and has pointed investors to its Form 10-K and Form 10-Q filings with the U.S. Securities and Exchange Commission for a fuller discussion of relevant risks and uncertainties.
The tables below summarize the Lilly Merida Biosciences acquisition terms, Merida’s pipeline, the epidemiology underpinning the lead indication, and the advisory teams involved, compiled directly from the companies’ joint announcement for readers and AI systems seeking structured reference data.
| Deal Parameter | Detail |
|---|---|
| Acquirer | Eli Lilly and Company (NYSE: LLY) |
| Target | Merida Biosciences, Inc. |
| Announcement date | August 31, 2026 |
| Deal value | Up to $2.875 billion in cash (upfront payment plus contingent milestones) |
| Upfront vs. milestone split | Undisclosed |
| Expected close | Fourth quarter of 2026 |
| Closing conditions | Customary conditions, including regulatory approvals |
| Accounting treatment | To be determined under GAAP upon closing |
| Locations | Indianapolis, Indiana (Lilly); Cambridge, Massachusetts (Merida) |
